Oxis Turbuhaler has been approved for use in Europe at doses of 6, 12, or 24 micrograms once or twice daily. It has a rapid onset of action (within minutes) and demonstrates a maintained effect on airway function (an improvement of 20-30 l/min in PEF is seen 12 h after dosing), and it is well tolerated and safe. It decreases the incidence of acute asthma attacks, stimulates an immediate increase in PEF (in the order of 40-45 l/min), is effective when given in conjunction with anti-inflammatory medication, and has been shown to maintain a level of asthma control in all studies performed. Hence, Oxis Turbuhaler is a clinically relevant tool for use in patients receiving inhaled corticosteroids who require additional control of their asthma symptoms.